Toll Free : + 1-888-961-4454 | Int'l : + 91 (788) 802-9103 | support@researchdive.com
LI23028643 |
Pages: 250 |
Feb 2023 |
The growing incidences of chronic diseases among people and rising hospitalization rate globally has triggered the growth of local anesthesia drugs market share growth in the forecast time. Chronic diseases like cancer and tumors require intense treatment which can cause intense pain in the patients’ body, thereby making then traumatic during treatment or surgical procedures. Local anesthesia helps in making the affected area numb so that the surgical procedure can be conducted smoothly and the patient is able to bear the pain. This factor is likely to drive the local anesthesia market share growth in the forecast time period.
The market growth is expected to be restricted in the forecast period owing to side effects caused by the anesthesia. Also, strict regulations imposed on the use of anesthesia drugs by the regulatory bodies is likely to impede local anesthesia drugs market growth in the forecast time period.
The introduction of novel and effective medications such as articaine and ropivacaine is further fueling the expansion of the market for local anesthesia drugs. This expansion is augmented by rising healthcare spending in developing countries such as India, China, and Brazil, where the number of surgeries performed has been steadily increasing.
Region-wise, the North America local anesthesia drugs market accounted for a dominating market share in 2021.
Local anesthesia is a temporary loss of sensation in a specific place or parts of the body. Local anesthesia drugs are used to treat uncomfortable circumstances, eliminate pain when performing large or minor surgeries, and reduce pain after surgery. At greater doses, certain drugs are utilized as local anesthetics. A local anesthetic can be administered directly into the affected area or absorbed through the skin. When a vast area needs to be anaesthetized or medications may not penetrate sufficiently, the doctor may use a different anesthetic that lasts 4 to 6 hours.
The COVID-19 pandemic has had a moderate impact on the local anesthesia drugs industry. Several swift alterations in reaction to COVID-19 had an immediate impact on local anesthetic medicines and their practices. Because of the lockdown, the supply chain for anesthesia drugs, globally, was slowed. The most difficult consequences resulted from the cancellation or postponing of non-essential surgical operations, which had a direct negative impact on the demand of anesthesia drugs. Anesthetics may reduce the effectiveness of a COVID-19 vaccination. This is due to the fact that a vaccine interacts with the immune system, as does anesthesia, both of which can interfere with how a vaccine teaches the body to fight infection. The American Society of Anesthesiologists recommends waiting at least two weeks following the last dose before undergoing anesthetic-assisted surgery.
However, the demand for local anesthesia was high owing to increased cases of viral infection and the high severity of symptoms observed in the patients. As the hospitalization rates increased in the pandemic era, the demand for anesthetic drugs also increased which has moderately impacted the market growth.
Rising cases of chronic diseases, like cancer and diabetes and high hospitalization rates due to these diseases, globally, is projected to drive the global local anesthesia market share growth in the forecast time period. Patients suffering from cancer, for instance, require hospitalizations, surgery, chemotherapy, anesthetic, and pain medication. Analgesia is routinely treated with opioids and local anesthetics. Also, rising incidences of surgeries, globally, owing to complications due to old age, accidents and dental treatments is expected to increase the demand for local anesthesia drugs. The growth in the number of surgeries performed can be attributed to the ageing population, which is more prone to chronic diseases such as cardiovascular disorders, respiratory ailments, cancer, neurological disorders, and various gastro, orthopedic, and spinal difficulties. For instance, according to a research paper ‘Trauma of major surgery: A global problem that is not going away’, published in September, 2022, worldwide, approximately 310 million major surgeries are performed every year out of which nearly 40 to 50 million surgeries take place in USA and 20 million in Europe. This factor is likely to drive the local anesthesia market in the forecast time period.
To know more about global local anesthesia drugs market drivers, get in touch with our analysts here.
Although, using local anesthesia is much better that using intravenous anesthesia, several side effects are also associated with it. Pain after injection, needle fracture, edema, anesthetic prolongation and numerous temporal abnormalities, trismus, inflammation, hematoma, skin injury, gingival lesions, and ocular complications are some common consequences that may limit market growth. Also, adoption of non-invasive surgeries that do not require the use of local anesthesia by patients and healthcare professionals is further likely to hinder local anesthesia drugs market revenue growth in the forecast time period.
The introduction of novel and effective medications such as articaine, and ropivacaine is further fueling the expansion of the market for local anesthesia drugs. For instance, according to a news published by American Hospital Association, on September 18, 2020, the Food and Drug Administration approved a new intravenous general anesthetic drug for propofol injectable emulsion. Also, increased reimbursement policies by the government and insurers for covering expensive surgeries has increased the number of patients opting for surgeries for various chronic diseases. This factor is further anticipated to drive market growth in the future. Also, the market expansion is augmented by rising healthcare spending in developing countries such as India, and Brazil, where the number of surgeries performed has been steadily increasing.
To know more about global local anesthesia drugs market opportunities, get in touch with our analysts here.
By drugs type, the market has been divided into bupivacaine, ropivacaine, lidocaine, chloroprocaine, prilocaine, benzocaine and other local anesthetics. Among these, the Lidocaine segment had a dominant market share in 2021 and Bupivacaine is anticipated to have the fastest growth in the forecast time period.
Source: Research Dive Analysis
The Lidocaine segment accounted for a dominant market share in 2021. Lidocaine is a type of local anesthetic. It is used to anaesthetize or numb the surgical area during small surgical operations such as dental, oral, diagnostic, or other therapeutic treatments. It is also used to provide brief relief from other skin, eye, or ear irritations. The market is expanding due to its widespread use as a topical and injectable anesthetic.
By application, the market has been divided into injectable and surface anesthetic. Among these, injectable segment had a dominant market share in 2021 and surface anesthetics is anticipated to have the fastest growth in the forecast time period.
Source: Research Dive Analysis
The injectable segment accounted for a dominant market share in 2021. This is primarily because injectable anesthetics are widely used in a variety of surgical procedures. Injectable anesthetics are typically utilized for numbing rather than pain management during procedures. A local anesthetic injection may be required for dental work such as a root canal, skin biopsy, removal of a growth under the skin, and removal of a mole.
The local anesthesia drugs market was analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Source: Research Dive Analysis
The North America local anesthesia drugs market size accounted for a dominating market share in 2021. The region offers tremendous growth opportunity for growth of local anesthesia drugs market. The market for local anesthesia drugs is expected to grow in North America because of a rise in the number of surgical procedures performed. The development of new anesthetic technologies for administration, as well as the rise in chronic diseases among the elderly, has fueled market expansion. The U.S. has the world's largest market share for anesthesia. Major players in the region with adequate investment in R&D for the manufacturing of revolutionary novel medications are a key component in the region's market growth. Also, established technologically advanced research and development centers and availability of experienced researchers to develop new drugs in the region is further anticipated to drive the market growth.
Investment and agreement are common strategies followed by major market players.
Source: Research Dive Analysis
The key players profiled in this report include Novartis AG, Aspen Pharmacare, Sagent Pharmaceuticals, Pacira Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi, Mylan N.V., GSK plc., AstraZeneca plc, and Hikma Pharmaceuticals plc.
| Aspect | Particulars |
| Historical Market Estimations | 2020 |
| Base Year for Market Estimation | 2020-2021 |
| Forecast Timeline for Market Projection | 2022-2031 |
| Geographical Scope | North America, Europe, Asia-Pacific, and LAMEA |
| Segmentation by Drug Type |
|
| Segmentation by Application |
|
| Key Companies Profiled |
|
1.Research Methodology
1.1.Desk Research
1.2.Real time insights and validation
1.3.Forecast model
1.4.Assumptions and forecast parameters
1.5.Market size estimation
1.5.1.Top-down approach
1.5.2.Bottom-up approach
2.Report Scope
2.1.Market definition
2.2.Key objectives of the study
2.3.Report overview
2.4.Market segmentation
2.5.Overview of the impact of COVID-19 on the global local anesthesia drugs market
3.Executive Summary
4.Market Overview
4.1.Introduction
4.2.Growth impact forces
4.2.1.Drivers
4.2.2.Restraints
4.2.3.Opportunities
4.3.Market value chain analysis
4.3.1.List of suppliers
4.3.2.List of manufacturers
4.3.3.List of distributors
4.4.Innovation & sustainability matrices
4.4.1.Technology matrix
4.4.2.Regulatory matrix
4.5.Porter’s five forces analysis
4.5.1.Bargaining power of suppliers
4.5.2.Bargaining power of consumers
4.5.3.Threat of substitutes
4.5.4.Threat of new entrants
4.5.5.Competitive rivalry intensity
4.6.PESTLE analysis
4.6.1.Political
4.6.2.Economical
4.6.3.Social
4.6.4.Technological
4.6.5.Environmental
4.7.Impact of COVID-19 on the local anesthesia drugs market
4.7.1.Pre-covid market scenario
4.7.2.Post-covid market scenario
5.Local Anesthesia Drugs Market Analysis, by Drug Type
5.1.Overview
5.2.Bupivacaine
5.2.1.Definition, key trends, growth factors, and opportunities
5.2.2.Market size analysis, by region, 2021-2031
5.2.3.Market share analysis, by country, 2021-2031
5.3.Ropivacaine
5.3.1.Definition, key trends, growth factors, and opportunities
5.3.2.Market size analysis, by region, 2021-2031
5.3.3.Market share analysis, by country, 2021-2031
5.4.Lidocaine
5.4.1.Definition, key trends, growth factors, and opportunities
5.4.2.Market size analysis, by region, 2021-2031
5.4.3.Market share analysis, by country, 2021-2031
5.5.Chloroprocaine
5.5.1.Definition, key trends, growth factors, and opportunities
5.5.2.Market size analysis, by region, 2021-2031
5.5.3.Market share analysis, by country, 2021-2031
5.6.Prilocaine
5.6.1.Definition, key trends, growth factors, and opportunities
5.6.2.Market size analysis, by region, 2021-2031
5.6.3.Market share analysis, by country, 2021-2031
5.7.Benzocaine
5.7.1.Definition, key trends, growth factors, and opportunities
5.7.2.Market size analysis, by region, 2021-2031
5.7.3.Market share analysis, by country, 2021-2031
5.8.Other Local Anesthetics
5.8.1.Definition, key trends, growth factors, and opportunities
5.8.2.Market size analysis, by region, 2021-2031
5.8.3.Market share analysis, by country, 2021-2031
5.9.Research Dive Exclusive Insights
5.9.1.Market attractiveness
5.9.2.Competition heatmap
6.Local Anesthesia Drugs Market Analysis, by Application
6.1.Overview
6.2.Injectable
6.2.1.Definition, key trends, growth factors, and opportunities
6.2.2.Market size analysis, by region, 2021-2031
6.2.3.Market share analysis, by country, 2021-2031
6.3.Surface Anesthetic
6.3.1.Definition, key trends, growth factors, and opportunities
6.3.2.Market size analysis, by region, 2021-2031
6.3.3.Market share analysis, by country, 2021-2031
6.4.Research Dive Exclusive Insights
6.4.1.Market attractiveness
6.4.2.Competition heatmap
7.Local Anesthesia Drugs Market, by Region
7.1.North America
7.1.1.U.S.
7.1.1.1.Market size analysis, by Drug Type
7.1.1.2.Market size analysis, by Application
7.1.2.Canada
7.1.2.1.Market size analysis, by Drug Type
7.1.2.2.Market size analysis, by Application
7.1.3.Mexico
7.1.3.1.Market size analysis, by Drug Type
7.1.3.2.Market size analysis, by Application
7.1.4.Research Dive Exclusive Insights
7.1.4.1.Market attractiveness
7.1.4.2.Competition heatmap
7.2.Europe
7.2.1.Germany
7.2.1.1.Market size analysis, by Drug Type
7.2.1.2.Market size analysis, by Application
7.2.2.UK
7.2.2.1.Market size analysis, by Drug Type
7.2.2.2.Market size analysis, by Application
7.2.3.France
7.2.3.1.Market size analysis, by Drug Type
7.2.3.2.Market size analysis, by Application
7.2.4.Spain
7.2.4.1.Market size analysis, by Drug Type
7.2.4.2.Market size analysis, by Application
7.2.5.Italy
7.2.5.1.Market size analysis, by Drug Type
7.2.5.2.Market size analysis, by Application
7.2.6.Rest of Europe
7.2.6.1.Market size analysis, by Drug Type
7.2.6.2.Market size analysis, by Application
7.2.7.Research Dive Exclusive Insights
7.2.7.1.Market attractiveness
7.2.7.2.Competition heatmap
7.3.Asia-Pacific
7.3.1.China
7.3.1.1.Market size analysis, by Drug Type
7.3.1.2.Market size analysis, by Application
7.3.2.Japan
7.3.2.1.Market size analysis, by Drug Type
7.3.2.2.Market size analysis, by Application
7.3.3.India
7.3.3.1.Market size analysis, by Drug Type
7.3.3.2.Market size analysis, by Application
7.3.4.Australia
7.3.4.1.Market size analysis, by Drug Type
7.3.4.2.Market size analysis, by Application
7.3.5.South Korea
7.3.5.1.Market size analysis, by Drug Type
7.3.5.2.Market size analysis, by Application
7.3.6.Rest of Asia-Pacific
7.3.6.1.Market size analysis, by Drug Type
7.3.6.2.Market size analysis, by Application
7.3.7.Research Dive Exclusive Insights
7.3.7.1.Market attractiveness
7.3.7.2.Competition heatmap
7.4.LAMEA
7.4.1.Brazil
7.4.1.1.Market size analysis, by Drug Type
7.4.1.2.Market size analysis, by Application
7.4.2.Saudi Arabia
7.4.2.1.Market size analysis, by Drug Type
7.4.2.2.Market size analysis, by Application
7.4.3.UAE
7.4.3.1.Market size analysis, by Drug Type
7.4.3.2.Market size analysis, by Application
7.4.4.South Africa
7.4.4.1.Market size analysis, by Drug Type
7.4.4.2.Market size analysis, by Application
7.4.5.Rest of LAMEA
7.4.5.1.Market size analysis, by Drug Type
7.4.5.2.Market size analysis, by Application
7.4.6.Research Dive Exclusive Insights
7.4.6.1.Market attractiveness
7.4.6.2.Competition heatmap
8.Competitive Landscape
8.1.Top winning strategies, 2021
8.1.1.By strategy
8.1.2.By year
8.2.Strategic overview
8.3.Market share analysis, 2021
9.Company Profiles
9.1.Novartis AG
9.1.1.Overview
9.1.2.Business segments
9.1.3.Product portfolio
9.1.4.Financial performance
9.1.5.Recent developments
9.1.6.SWOT analysis
9.2.Aspen Pharmacare
9.2.1.Overview
9.2.2.Business segments
9.2.3.Product portfolio
9.2.4.Financial performance
9.2.5.Recent developments
9.2.6.SWOT analysis
9.3.Sagent Pharmaceuticals, Inc.
9.3.1.Overview
9.3.2.Business segments
9.3.3.Product portfolio
9.3.4.Financial performance
9.3.5.Recent developments
9.3.6.SWOT analysis
9.4.Teva Pharmaceutical Industries Ltd.
9.4.1.Overview
9.4.2.Business segments
9.4.3.Product portfolio
9.4.4.Financial performance
9.4.5.Recent developments
9.4.6.SWOT analysis
9.5.Pacira Pharmaceuticals, Inc.
9.5.1.Overview
9.5.2.Business segments
9.5.3.Product portfolio
9.5.4.Financial performance
9.5.5.Recent developments
9.5.6.SWOT analysis
9.6.Fresenius Kabi
9.6.1.Overview
9.6.2.Business segments
9.6.3.Product portfolio
9.6.4.Financial performance
9.6.5.Recent developments
9.6.6.SWOT analysis
9.7.Mylan N.V.
9.7.1.Overview
9.7.2.Business segments
9.7.3.Product portfolio
9.7.4.Financial performance
9.7.5.Recent developments
9.7.6.SWOT analysis
9.8.GSK plc.
9.8.1.Overview
9.8.2.Business segments
9.8.3.Product portfolio
9.8.4.Financial performance
9.8.5.Recent developments
9.8.6.SWOT analysis
9.9.AstraZeneca plc
9.9.1.Overview
9.9.2.Business segments
9.9.3.Product portfolio
9.9.4.Financial performance
9.9.5.Recent developments
9.9.6.SWOT analysis
9.10.Hikma Pharmaceuticals plc
9.10.1.Overview
9.10.2.Business segments
9.10.3.Product portfolio
9.10.4.Financial performance
9.10.5.Recent developments
9.10.6.SWOT analysis
* Taxes/Fees, If applicable will be added during checkout. All prices in USD.
Have a question ?
Enquire To BuyNeed to add more ?
Request Customization
